, Volume 35, Issue 1, pp 1–21 | Cite as


A Preliminary Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy in Hypertension and Angina Pectoris
  • William H. Frishman
  • Renée J. Goldberg
  • Paul Benfield
Drug Evaluation



Bevantolol is a new β- adrenoceptor antagonist which possesses a relatively high degree of selectivity for β1- adrenoceptors. It is devoid of intrinsic sympathomimetic activity and possesses only weak local anaesthetic properties. Interestingly, bevantolol has been shown to cause a lowering effect on peripheral vascular resistance. Available clinical data indicate that bevantolol, given once or twice daily, is an effective agent in the management of mild to moderate hypertension and stable angina pectoris. In hypertension bevantolol has been shown to be of comparable therapeutic efficacy to both atenolol and propranolol, while in patients with angina pectoris the drug compared favourably with atenolol. During short and long term administration bevantolol has been well tolerated and few patients have withdrawn from treatment because of adverse effects.

However, although the properties of bevantolol may offer theoretical advantages in some patients, only a few comparative studies have been reported, and thus it is presently unclear what advantages bevantolol may offer over existing treatments for hypertension or angina pectoris.

Pharmacodynamic Properties

Studies in animals and man have shown that bevantolol is a relatively selective β1- adrenoceptor antagonist. In vitro and in vivo, bevantolol inhibited the chronotropic response to isoprenaline (isoproterenol) in various species, and in the anaesthetised dog it also inhibited tachycardia induced by adrenaline (epinephrine), carotid artery occlusion, tyramine and 1,1-dimethyl-4-phenylpiperazinium iodide. Animal studies have shown the β-adrenoceptor blocking potency of bevantolol to be between 3- and 8-fold less than that of propranolol after intravenous and oral administration. The selectivity of bevantolol for β1-adrenoceptors was demonstrated in vitro by its significantly greater antagonism of guinea-pig atrial versus tracheal response to isoprenaline. In dogs bevantolol produced more selective blockade of the chronotropic versus the depressor cardiovascular responses to isoprenaline than propranolol. In humans bevantolol 200 mg/day reduced the chronotropic effect of isoprenaline to a similar extent as atenolol 100 mg/day.

Bevantolol does not possess intrinsic sympathomimetic activity and it is only a weak local anaesthetic. In receptor binding studies bevantolol displayed weak affinity for α1-adrenoceptors and an antagonist effect has been demonstrated in vitro but it is not known whether this represents a clinically significant effect.

It has been demonstrated in animals and humans that bevantolol, mainly as a result of β1-adrenoceptor antagonism, exerts a negative chronotropic effect on the heart. In healthy human subjects single oral doses of bevantolol 50 or 100mg reduced tachycardia and elevated blood pressure caused by exercise. In patients with hypertension, administration of bevantolol 200 to 600 mg/day either as single or divided daily doses significantly reduced heart rate over a 24-hour period. In addition, during treatment of patients with angina pectoris heart rate significantly reduced after 2 weeks and this reduction was maintained for up to 12 weeks in treatment with bevantolol 300 mg/day. The results of a study in a small number of healthy subjects and patients with slight to moderate ischaemic heart disease suggest that bevantolol also exerts negative inotropic effects on the myocardium. Administration of bevantolol 200 mg/day orally to healthy subjects for 7 days caused an overall reduction in peripheral vascular resistance. The blood pressure lowering effects of bevantolol have been demonstrated in hypertensive rats, normotensive dogs and in healthy volunteers as well as patients with hypertension. In healthy subjects, administration of bevantolol 200mg daily for 7 days caused a reduction in peripheral resistance.

Several studies in animal models of myocardial ischaemia have shown that bevantolol produced increased blood flow and improved contractile function of ischaemic myocardium. It has also been shown that bevantolol decreased the extent of epicardial ST segment shift in dogs and protected the ischaemic myocardium from ventricular fibrillation in pigs.

Bevantolol, administered as single or cumulative doses, has been shown to reduce the FEV1 in small numbers of patients with asthma but the risk of bronchospasm occurring in such patients during treatment for hypertension is not known.

During 12 weeks’ administration to patients with angina pectoris bevantolol 300 mg/ day reduced the serum low density lipoprotein concentration and increased the high density lipoprotein/low density lipoprotein ratio. However, bevantolol affected neither fasting plasma insulin concentrations in these patients nor fasting blood glucose concentrations in patients with both hypertension and mild diabetes. These apparently beneficial effects of bevantolol on the blood lipid profile were not confirmed in patients with hypertension treated for 6 months.

Pharmacokinetic Properties

After single doses of bevantolol 100 to 400mg in fasted healthy subjects, peak plasma concentrations occur between 1 and 2 hours. While absorption of bevantolol is nearly complete, it undergoes presystemic metabolism — about 60% of an orally administered dose reaches the systemic circulation in unchanged form. Although food may slow the rate of absorption of bevantolol, the total amount of drug absorbed is not significantly affected. Distribution is rapid and extensive. In man, the apparent volume of distribution is 1.5 L/kg. Over 95% of plasma bevantolol is bound to glycoproteins.

Less than 10% of an oral dose of bevantolol appears unchanged in the urine. Several metabolites have been identified, although none are considered to be of clinical importance. Most (72%) of a radioactive dose of bevantolol is renally excreted over 5 days. In healthy subjects the mean elimination half-life of bevantolol was about 1.5 hours and there were no recorded changes in pharmacokinetic variables after 7 daily doses of 100 or 200mg.

Current evidence suggests that the pharmacokinetic properties of bevantolol do not change to a clinically significant extent in the elderly or patients with renal impairment.

Therapeutic Trials

In patients with mild to moderate hypertension single or divided daily doses of bevantolol 200, 300 or 400mg reduced diastolic blood pressure to a significantly greater extent than placebo. After up to 11 weeks’ treatment with bevantolol 100 to 400 mg/day between 66 and 79% of patients had attained a clinical response compared with 23 to 33% of patients administered placebo. Daily doses of bevantolol 200, 300 and 400mg appear to be therapeutically equivalent in patients with mild to moderate hypertension. Using 24-hour blood pressure recordings, it was shown that the antihypertensive effects of once or twice daily administration are similar. In addition, bevantolol blunted the early morning increase in blood pressure. Administration of twice daily doses of bevantolol 100 to 300mg or propranolol 80 to 240mg for 6 months produced equivalent antihypertensive effects. In addition, bevantolol 400 mg/day appears to be similar in antihypertensive efficacy to atenolol 100 mg/day, when both are administered as once daily regimens.

In patients with stable angina pectoris bevantolol 75 or 150mg twice daily significantly reduced both the myocardial oxygen demand during maximum workload and the proportion of patients who stopped exercising because of angina pain or ST segment depression. In addition, the frequency of angina attacks was reduced and the patients’ ‘quality of life’ improved after bevantolol. Another study showed that indices of antianginal efficacy were similarly improved after bevantolol 200 mg/day was administered as a once or twice daily dosage regimen.

Bevantolol 150mg twice daily and atenolol 100mg once daily displayed similar anti-anginal effects when administered over 12 weeks, with the exception that both resting and exercise heart rate were reduced to a greater extent after atenolol. Another study showed that once daily administration of bevantolol 400mg or atenolol 100mg for 4 weeks caused significant antianginal effects with no between-treatment differences.

Side Effects

Bevantolol has been well tolerated during short and long term studies in hypertension and angina pectoris. The most frequently reported side effects were fatigue, headache, dizziness, oedema and gastrointestinal upsets. These have generally been mild, causing only few patients to withdraw from treatment.

Dosage and Administration

Most patients with mild to moderate hypertension or angina pectoris should respond to doses of bevantolol within the ranges of 200 to 400 mg/day or 150 to 300 mg/day, respectively. A once or twice daily dosage regimen, individually titrated for optimum efficacy, may be used.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Al-Khawaja IM, Caruana MP, Prince H, Whittington J, Raftery EB. Once- and twice-daily bevantolol for systemic hypertension using 24-hour ambulatory intraarterial blood pressure recording. American Journal of Cardiology 58: 17E–20E, 1986PubMedCrossRefGoogle Scholar
  2. Avery GS, Heel RC, Speight TM. Appendix B: guide to adverse drug reactions. In Avery (Ed.) Drug treatment, 2nd ed., pp. 1224–1251, ADIS Press, Sydney, 1980Google Scholar
  3. Becker LC, Fortuin NJ, Pitt P. The effect of ischemia and antianginal drugs on the distribution of radioactive microspheres in the canine left ventricle. Clinical Research 28: 263–269, 1971Google Scholar
  4. Berdeaux A, Boissier JR, Guidicelli JF. Effects of atenolol on regional myocardial blood flow and ST-segment elevation in the canine myocardium. British Journal of Pharmacology 60: 433–439, 1977CrossRefGoogle Scholar
  5. Bianchi C. A simple new quantitative method for testing local anesthetics. British Journal of Pharmacology 11: 104–106, 1956Google Scholar
  6. Bowles MJ, Khurmi NS, O’Hara MJ, Raftery EB. Usefulness of bevantolol for chronic, stable angina. American Journal of Cardiology 58: 28E–34E, 1986PubMedCrossRefGoogle Scholar
  7. Braunwald E. Mechanism of action of calcium-channel-blocking agents. New England Journal of Medicine 307: 1618–1627, 1982PubMedCrossRefGoogle Scholar
  8. Bray JS. Safety profile of bevantolol. Angiology 37: 248–253, 1986PubMedCrossRefGoogle Scholar
  9. Buck JD, Gross GJ, Warltier DC, Jolly SR, Hardman HF. Comparative effects of cardioselective versus noncardioselective beta blockade on subendocardial blood flow and contractile function in ischemic myocardium. American Journal of Cardiology 44: 657–663, 1979PubMedCrossRefGoogle Scholar
  10. Caponnetto S, Canale C, Mereto PE, Terrachini V, Lacapra P, et al. Bicycle ergometer testing comparison of bevantolol and atenolol in the treatment of effort-induced chronic angina pectoris. Current Therapeutic Research 41: 226–233, 1987Google Scholar
  11. Chiodini G, Bertolini S, Elicio N, Reggiani E, Valice S. Bevantolol versus propranolol in hypertensive non-insulin-dependent diabetics. Current Therapeutic Research 38: 586–591, 1985Google Scholar
  12. Cleaveland CR, Rango RE, Shand DG. A standardized isoproterenol sensitivity test. Archives of Internal Medicine 130: 47–52, 1972PubMedCrossRefGoogle Scholar
  13. Cooke ED, Maltz MB, Smith RE, Bowcock SA, Watkins CJ, et al. Peripheral vascular effects of β-adrenoceptor blockade: comparison of two agents. British Journal of Clinical Pharmacology 24: in press, 1987Google Scholar
  14. Dukes JD, Vaughan Williams EM. Cardiovascular effects of bevantolol, a selective β1-adrenoceptor with a novel pharmacologic profile. British Journal of Pharmacology 84: 365–380, 1985PubMedCrossRefGoogle Scholar
  15. Farnham DJ. Effectiveness of bevantolol in the treatment of angina — a placebo-controlled study. Angiology 37: 226–232, 1986PubMedCrossRefGoogle Scholar
  16. Foster-Vickers F. Other β-adrenoceptor antagonists. In Scriabine (Ed.) Pharmacology of antihypertensive drugs, pp. 349–365, Raven Press, New York, 1980Google Scholar
  17. Gribbin HR, Baldwin CJ, Tattersfield AF. Quantitative assessment of bronchial beta-adrenoceptor blockade in man. British Journal of Clinical Pharmacology 7: 551–556, 1979PubMedCrossRefGoogle Scholar
  18. Gross GJ, Buck JD, Warltier DC, Hardman HF. Beneficial actions of bevantolol on subendocardial blood flow and contractile function in ischemic myocardium. Journal of Cardiovascular Pharmacology 1: 139–147, 1979PubMedCrossRefGoogle Scholar
  19. Gross GJ, Winbury MM. Beta adrenergic blockade on intramyocardial distribution of coronary blood flow. Journal of Pharmacology and Experimental Therapeutics 187: 451–464, 1973PubMedGoogle Scholar
  20. Hartog JM, van Bremen RH, Verdouw PD. On the cardiovascular and antiarrhythmic actions of the cardioselective beta-adrenoceptor antagonist bevantolol in the pig. Drug Development Research 7: 23–33, 1986CrossRefGoogle Scholar
  21. Hastings SG, Haleen SJ. The effects of the cardioselective beta-blocker (CI-775) in experimental myocardial ischemia. Federation Proceedings 34: 721, 1975Google Scholar
  22. Hastings SG, Smith RD, Corey RM, Essenburg AD, Pettway CE, et al. Pharmacologic evaluation of CI-775, a cardioselective beta adrenergic antagonist. Archives of International Pharmacodynamics 226: 81–99, 1977Google Scholar
  23. Jain A. Effectiveness of bevantolol in the treatment of hypertension: once-daily versus twice-daily evaluation of home blood pressure measurements. Angiology 37: 239–245, 1986PubMedCrossRefGoogle Scholar
  24. Kaplan HR, Chang T, Eckerson HW, Tessman DK. Bevantolol hydrochloride. In Scriabine (Ed.) New drugs annual, pp. 85–97, Raven Press, New York, 1985Google Scholar
  25. Kaplan HR. Bevantolol hydrochloride — preclinical pharmacologic profile. Angiology 37: 254–262, 1986PubMedCrossRefGoogle Scholar
  26. Koskinen P, Pellinen TJ. Effects of bevantolol and propranolol on blood pressure, serum lipids, and lipoproteins in essential hypertension. Current Therapeutic Research 41: 952–960, 1987Google Scholar
  27. Lammers J-WJ, Folgering HTM, van Herwaarden CLA. Ventilatory effects of atenolol and bevantolol in asthma. Clinical Pharmacology and Therapeutics 38: 428–433, 1985PubMedCrossRefGoogle Scholar
  28. Latts JR. Clinical pharmacokinetics and metabolism of bevantolol. Angiology 37: 221–225, 1986PubMedCrossRefGoogle Scholar
  29. Löfdahl C-G, Svedmyr K, Svedmyr N. Selectivity of bevantolol hydrochloride, a β1-adrenoceptor antagonist, in asthmatic patients. Pharmacotherapy 4: 205–210, 1984PubMedGoogle Scholar
  30. Mackay AD, Gribbin HR, Baldwin CJ, Tattersfield AE. Assessment of bronchial beta blockade after oral bevantolol. Clinical Pharmacology and Therapeutics 29: 1–6, 1981PubMedCrossRefGoogle Scholar
  31. Marshall RL, Parratt JR. Comparative effects of propranolol and practolol in the early stages of experimental canine myocardial infarction. British Journal of Pharmacology 57: 295–303, 1976PubMedCrossRefGoogle Scholar
  32. McDevitt DG. Clinical significance of cardioselectivity: state of the art. Drugs 25 (Suppl. 2): 219–226, 1983CrossRefGoogle Scholar
  33. Okawa KK. Dose-response studies of bevantolol in hypertensive patients. Angiology 37: 233–235, 1986PubMedCrossRefGoogle Scholar
  34. Patel L, Turner P. Central actions of β-adrenoceptor blocking drugs in man. Medicinal Research Reviews 1: 387–410, 1981PubMedCrossRefGoogle Scholar
  35. Paterson JW, Conolly ME, Dollery CT, Hayes A, Cooper RG. The pharmacodynamics and metabolism of propranolol in man. Clinical Pharmacy 2: 127–133, 1970CrossRefGoogle Scholar
  36. Raftery EB, Carrageta MO. Hypertension and beta-blockers: are they all the same? International Journal of Cardiology 7: 337–346, 1985PubMedCrossRefGoogle Scholar
  37. Randinitis EJ, Nelson C, Kinkel A, Campese V, Welling P. Pharmacokinetics of bevantolol in patients with varying degrees of renal failure. Pharmaceutical Research 4 (Suppl.): 5–89, 1987CrossRefGoogle Scholar
  38. Regardh CG. Pharmacokinetic aspects of some β-adrenoceptor blocking drugs. Acta Medica Scandinavica (Suppl. 665): 49–60, 1982Google Scholar
  39. Salonen JT, Taskinen E, Salonen R, Seppänen K, Venäläinen J, et al. Effects of bevantolol and atenolol on symptoms, exercise tolerance and metabolic risk factors in angina pectoris. American Journal of Cardiology 58: 35E–40E, 1986PubMedCrossRefGoogle Scholar
  40. Scheidt S. The role of calcium blockers in the treatment of chronic stable angina. In Flaim SF & Zelis R (Eds) Calcium blockers: mechanisms of action and clinical applications, pp. 231–244, Urban and Schwarzenberg, Baltimore, 1982Google Scholar
  41. Selen A, Kinkel AW, Darke AC, Greene DS, Welling PG. Comparative single dose and steady-state pharmacokinetics of bevantolol in young and elderly subjects. European Journal of Clinical Pharmacology 30: 699–704, 1986PubMedCrossRefGoogle Scholar
  42. Simpson FO. Hypertensive disease. In Speight (Ed.) Avery’s drug treatment, 3rd ed., Chap. 18, ADIS Press, Auckland, 1987Google Scholar
  43. Sloman JG, Manolas E. Cardiovascular diseases. In Avery (Ed.) Drug treatment, 2nd ed., pp. 554–637, ADIS Press, Sydney, 1980Google Scholar
  44. Théroux P, Waters DD, Debaisieux JC, Szlachcic J, Micgala HF, et al. Hemodynamic effects of calcium ion antagonists after acute myocardial infarction. Clinical and Investigative Medicine 3: 81–85, 1983Google Scholar
  45. Toothaker RD, Randinitis EJ, Nelson C, Kinkel AW, Goulet JR. The influence of food on the oral absorption of bevantolol. Journal of Clinical Pharmacology 27: 297–299, 1987PubMedGoogle Scholar
  46. Trieb G, Sigwart U. Die Wirkung des neuen Beta-Rezeptoren-blockers Bevantolol (CI 775) auf die linksventrikuläre Ruhe-und Belastungshämodynamik. Herz 3: 276–287, 1978PubMedGoogle Scholar
  47. Vatner SF, Baig H, Manders WT, Och H, Pagani M. Effects of propranolol on regional myocardial function, electrograms, and blood flow in conscious dogs with myocardial ischemia. Journal of Clinical Investigation 60: 353–360, 1977PubMedCrossRefGoogle Scholar
  48. Verdouw PD, Van Bremen RH, Verkeste CM, Van Der Giessen WJ. Antiarrhythmic action and protection of ischemic myocardium after beta-blockade with bevantolol. European Journal of Pharmacology 111: 377–380, 1985PubMedCrossRefGoogle Scholar
  49. Waal-Manning HJ. Hypertension: which beta-blocker? Drugs 13: 412–441, 1976CrossRefGoogle Scholar
  50. Warltier DC, Gross GJ, Hardman HF. Effect of propranolol on regional myocardial blood flow and oxygen consumption. Journal of Pharmacology and Experimental Therapeutics 198: 435–443, 1976PubMedGoogle Scholar
  51. Warltier DC, Gross GJ, Jesmok GJ, et al. Protection of ischemic myocardium: comparison of effects of propranolol, bevantolol, and n-dimethyl propranolol on infarct size following coronary occlusion in anesthetized dogs. Cardiology 66. 133–146, 1980PubMedCrossRefGoogle Scholar
  52. Wilcox PG, Ahmad D, Darke AC, Parsons J, Carruthers SG. Respiratory and cardiac effects of metoprolol and bevantolol in patients with asthma. Clinical Pharmacology and Therapeutics 39: 29–34, 1986PubMedCrossRefGoogle Scholar

Copyright information

© ADIS Press Limited 1988

Authors and Affiliations

  • William H. Frishman
    • 1
    • 2
    • 3
  • Renée J. Goldberg
    • 1
    • 2
    • 3
  • Paul Benfield
    • 1
    • 2
    • 3
  1. 1.Department of MedicineAlbert Einstein College of MedicineBronxUSA
  2. 2.Department of Pharmacology, Arnold and Marie Schwartz College of Pharmacy and Health SciencesLong Island UniversityBrooklynUSA
  3. 3.ADIS Drug Information ServicesMairangi Bay, Auckland 10New ZealandUSA

Personalised recommendations